PSD Bank Westfalen-Lippe eG

Suchergebnis - GALAPAGOS N.V. ACTIONS NOM. O.N.

Zeit	Titel
02.05 22:01	dpa-AFX: GNW-Adhoc: Galapagos reports first quarter 2024 financial results
04.04 22:01	dpa-AFX: GNW-Adhoc: Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
22.02 22:01	dpa-AFX: GNW-Adhoc: Galapagos announces full year 2023 results and outlook for 2024
19.12 22:01	dpa-AFX: GNW-Adhoc: Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
02.11 21:01	dpa-AFX: GNW-Adhoc: Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
19.09 22:01	dpa-AFX: GNW-Adhoc: Galapagos appoints Simon Sturge to its Board of Directors
28.08 22:01	dpa-AFX: GNW-Adhoc: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
03.08 22:01	dpa-AFX: GNW-Adhoc: Galapagos announces first half-year 2023 financial results
15.06 22:01	dpa-AFX: GNW-Adhoc: Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
12.06 22:01	dpa-AFX: GNW-Adhoc: Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
31.05 07:54	dpa-AFX: *UBS STARTET GALAPAGOS NV MIT 'NEUTRAL' - ZIEL 40 EUR
31.05 07:54	dpa-AFX: *UBS STARTS GALAPAGOS NV WITH 'NEUTRAL' - PRICE TARGET 40 EUR
23.05 22:01	dpa-AFX: GNW-Adhoc: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis